| Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1851 | 2015 |
| Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1443 | 2021 |
| Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma N Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ... New England Journal of Medicine 380 (18), 1726-1737, 2019 | 1423 | 2019 |
| Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma FE Davies, N Raje, T Hideshima, S Lentzsch, G Young, YT Tai, B Lin, ... Blood, The Journal of the American Society of Hematology 98 (1), 210-216, 2001 | 1224 | 2001 |
| Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy T Hideshima, D Chauhan, Y Shima, N Raje, FE Davies, YT Tai, SP Treon, ... Blood, The Journal of the American Society of Hematology 96 (9), 2943-2950, 2000 | 1209 | 2000 |
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, ... Blood, The Journal of the American Society of Hematology 116 (5), 679-686, 2010 | 1031 | 2010 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 870 | 2019 |
| Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma L Santo, T Hideshima, AL Kung, JC Tseng, D Tamang, M Yang, M Jarpe, ... Blood, The Journal of the American Society of Hematology 119 (11), 2579-2589, 2012 | 656 | 2012 |
| Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration K Podar, YT Tai, FE Davies, S Lentzsch, M Sattler, T Hideshima, BK Lin, ... Blood, The Journal of the American Society of Hematology 98 (2), 428-435, 2001 | 587 | 2001 |
| Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells T Hideshima, L Catley, H Yasui, K Ishitsuka, N Raje, C Mitsiades, K Podar, ... Blood 107 (10), 4053-4062, 2006 | 510 | 2006 |
| Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma M Fulciniti, P Tassone, T Hideshima, S Vallet, P Nanjappa, SA Ettenberg, ... Blood, The Journal of the American Society of Hematology 114 (2), 371-379, 2009 | 469 | 2009 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 446 | 2014 |
| Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells T Hideshima, H Ikeda, D Chauhan, Y Okawa, N Raje, K Podar, ... Blood, The Journal of the American Society of Hematology 114 (5), 1046-1052, 2009 | 445 | 2009 |
| International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ... Journal of clinical oncology 31 (18), 2347, 2013 | 441 | 2013 |
| Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans GT Görgün, G Whitehill, JL Anderson, T Hideshima, C Maguire, ... Blood, The Journal of the American Society of Hematology 121 (15), 2975-2987, 2013 | 419 | 2013 |
| Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, ... Journal of Clinical Oncology 33 (6), 657-664, 2015 | 415 | 2015 |
| Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study N Raje, E Terpos, W Willenbacher, K Shimizu, R García-Sanz, B Durie, ... The Lancet Oncology 19 (3), 370-381, 2018 | 391 | 2018 |
| In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells D Chauhan, Z Tian, B Zhou, D Kuhn, R Orlowski, N Raje, P Richardson, ... Clinical cancer research 17 (16), 5311-5321, 2011 | 384 | 2011 |
| Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application T Hayashi, T Hideshima, M Akiyama, K Podar, H Yasui, N Raje, S Kumar, ... British journal of haematology 128 (2), 192-203, 2005 | 383 | 2005 |
| Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells AM Roccaro, T Hideshima, N Raje, S Kumar, K Ishitsuka, H Yasui, ... Cancer research 66 (1), 184-191, 2006 | 380 | 2006 |
